Further Development of an Exhaled microRNA Biomarker of Lung Cancer Risk
Technical Report,15 Jul 2016,14 Jul 2017
Albert Einstein College of Medicine, Inc. Bronx United States
Pagination or Media Count:
We seek to devise a non-invasive airway based exhaled microRNA metric for lung cancer risk, initial work to be tested in a case control study. We expanded the microRNA panel to 30microRNAs, and expanded the cohort beyond Einstein-MontefioreBronx to include Bronx J Peters VAH clinic-based recruits, in a case-control study. We also expanded the assessment of lung cancer subjects to also include limited 3-month prospective follow-up of non-cancer controls in order to minimize control contaminationmisclassification, and improved matching on age, smoking status, and underlying COPD initial n90 versus n90 controls. In essence we were able to detect a discriminant signature from exhaled microRNAs, whereby discriminant accuracy over and above clinical criteria alone, was improved by 3-8.
- Medicine and Medical Research